<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616924</url>
  </required_header>
  <id_info>
    <org_study_id>RHB-204-01</org_study_id>
    <nct_id>NCT04616924</nct_id>
  </id_info>
  <brief_title>RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease</brief_title>
  <acronym>CleaR-MAC</acronym>
  <official_title>Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease in Adults With Nodular Bronchiectasis (CleaR-MAC Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedHill Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedHill Biopharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group&#xD;
      study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying&#xD;
      nodular bronchiectasis and documented MAC lung infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group&#xD;
      study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying&#xD;
      nodular bronchiectasis and documented MAC lung infection.&#xD;
&#xD;
      The co-primary efficacy endpoints at the end of Part 1 evaluate the proportion of patients&#xD;
      with sputum culture conversion after 6 months of treatment defined as three consecutive&#xD;
      monthly negative sputum cultures at Months 4, 5, and 6 for RHB-204 compared to placebo and&#xD;
      the mean change in the Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory&#xD;
      Symptoms domain score from baseline to Month 6 for RHB-204 compared to placebo.&#xD;
&#xD;
      At the Month 6 visit (end of Part 1), after all assessments including questionnaires and&#xD;
      sputum samples have been collected, subjects will enter Part 2 of the study and receive&#xD;
      open-label RHB-204 for 10 months to Month 16, followed by a post-treatment follow-up visit 3&#xD;
      months later, at Month 19.&#xD;
&#xD;
      Patient reported outcomes and durability of microbiological response will be assessed at&#xD;
      Month 6 and Month 19 (3 months post-completion of treatment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life Questionnaire - Bronchiectasis (QoL B) Respiratory Symptoms domain score</measure>
    <time_frame>6 months</time_frame>
    <description>The mean change in the Quality of Life Questionnaire - Bronchiectasis (QoL B) Respiratory Symptoms domain score from baseline to Month 6 for RHB-204 compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sputum culture conversion (SCC)</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of subjects who achieve SCC by Month 6. This will be evaluated at Month 6 whereby SCC is defined by at least 3 prior consecutive negative monthly sputum cultures at Month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 Secondary efficacy objective - Reduction of fatigue</measure>
    <time_frame>6 months</time_frame>
    <description>The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 6 for RHB-204 compared to placebo. The PROMIS Fatigue SF 8a is scored out of 40, whereby a score of 40 is the worst a patient can feel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 Secondary efficacy objective - Time to culture conversion</measure>
    <time_frame>6 months</time_frame>
    <description>The time to SCC (month of first negative sputum culture) for RHB-204 compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 Secondary efficacy objective - Improvement in Physical Functioning</measure>
    <time_frame>6 months</time_frame>
    <description>The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 6 for RHB-204 compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Secondary efficacy objective - Durable Sputum culture conversion at end of study</measure>
    <time_frame>19 months</time_frame>
    <description>The proportion of subjects with SCC by Month 6 who sustain negative sputum cultures at Month 16 and negative sputum culture at Month 19 (3 months off treatment) for RHB-204 compared to placebo (durable responders).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Secondary efficacy objective - Durable Sputum culture conversion at end of treatment</measure>
    <time_frame>16 months</time_frame>
    <description>Measure the proportion of subjects with SCC by Month 6 who sustain negative sputum cultures at Month 16 for RHB-204 compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL B Respiratory Symptoms domain score mean change from baseline to Month 16</measure>
    <time_frame>16 months</time_frame>
    <description>The mean change in Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms domain scores from baseline to Month 16 for ex-RHB-204 compared to ex-placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Secondary efficacy objective - Improvement in Quality of Life - Fatigue 16 months</measure>
    <time_frame>16 months</time_frame>
    <description>The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 16 for ex-RHB-204 compared to ex-placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Secondary efficacy objective - Improvement in Quality of Life - Fatigue 19 Months</measure>
    <time_frame>19 months</time_frame>
    <description>The mean change in the PROMIS Fatigue SF 8a score from baseline to Month 19 for ex-RHB-204 compared to ex-placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Secondary efficacy objective - Quality of Life Physical Functioning Symptoms 16 Months</measure>
    <time_frame>16 months</time_frame>
    <description>The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 16 for ex-RHB-204 compared to ex-placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Secondary efficacy objective - Quality of Life Physical Functioning Symptoms 19 Months</measure>
    <time_frame>19 Months</time_frame>
    <description>The mean change in the Short Form 36 Physical Functioning domain score from baseline to Month 19 for ex-RHB-204 compared to ex-placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL-B Respiratory Symptoms domain scores at Month 19</measure>
    <time_frame>19 Months</time_frame>
    <description>The mean change in Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms domain scores from baseline to Month 19 for ex-RHB-204 compared to ex-placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Pulmonary Mycobacterium Avium Complex Infection</condition>
  <condition>Bronchiectasis</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>RHB-204</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each capsule contains clarithromycin 158.3mg; rifabutin 40mg; clofazimine 13.3mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will contain riboflavin, a type of B vitamin, which may discolor urine in a similar fashion as RHB-204.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHB-204</intervention_name>
    <description>RHB-204</description>
    <arm_group_label>RHB-204</arm_group_label>
    <other_name>Clarithromycin 158.3mg, Rifabutin 40mg and Clofazimine 13.3mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to RHB-204</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          -  Males and females aged ≥18 years to ≤85 years of age, inclusively&#xD;
&#xD;
          -  Have a MAC lung infection documented by one MAC positive culture within 18 months&#xD;
             prior to screening and a MAC positive culture at screening (cultures need to be at&#xD;
             least 1 month apart). Prior sputum for culture may be obtained from sputum or&#xD;
             bronchial washings however, sputum collected during screening must be either&#xD;
             spontaneously expectorated by the patient or after sputum induction.&#xD;
&#xD;
          -  Have MAC lung infection with evidence of underlying nodular infiltrates and/or&#xD;
             bronchiectasis on a chest computed tomography (Chest CT) within 6 months of screening.&#xD;
&#xD;
          -  Have symptoms of MAC lung infection that include one of the following: respiratory&#xD;
             symptoms such as chronic cough, excessive mucous production, fatigue, dyspnea,&#xD;
             hemoptysis or systemic symptoms such as fever, night sweats or loss of appetite.&#xD;
&#xD;
          -  Be treatment naïve, or if previously treated for MAC, have not received treatment&#xD;
             within the 6 months prior to screening&#xD;
&#xD;
          -  Subject's weight is above 41 Kilograms or 90 pounds.&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          -  Cavitary lung disease as observed on a chest CT scan (cavitary lesions exceeding 2 cm&#xD;
             in diameter).&#xD;
&#xD;
          -  Currently taking or treated in the 6 months prior to screening with any of the&#xD;
             following: bedaquiline, clofazimine or any component of American Thoracic&#xD;
             Society(ATS)/Infectious Diseases Society of America (IDSA) multi-drug recommended&#xD;
             therapy (macrolides, ethambutol, rifabutins/rifampins) for MAC or other multi-drug&#xD;
             regime for NTM lung disease&#xD;
&#xD;
          -  Clarithromycin minimum inhibitory concentration (MIC) ≥32μg/mL on MAC isolates in&#xD;
             screening sputum&#xD;
&#xD;
          -  Known hypersensitivity or suspected history of hypersensitivity reactions to&#xD;
             clarithromycin, rifabutin, or clofazimine or other drugs in each class&#xD;
&#xD;
          -  Subjects requiring chronic supplemental oxygen use (including intermittent or&#xD;
             continuous use)&#xD;
&#xD;
          -  Planned lung resection surgery for MAC lung disease&#xD;
&#xD;
          -  Subjects with Cystic Fibrosis, prior solid organ or hematologic transplant&#xD;
&#xD;
          -  Current usage of inhaled products containing amikacin, tobramycin or gentamicin&#xD;
&#xD;
          -  History of ventricular arrhythmias or family history of Long QT syndrome, including&#xD;
             torsades de pointes&#xD;
&#xD;
          -  Corrected QT (QTc) interval on electrocardiogram (ECG) &gt;460 ms for females or &gt;450 ms&#xD;
             for males, calculated using Fridericia's formula (QTcF)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin L. Winthrop, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>June L Almenoff, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>RedHill Biopharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aida Bibliowicz, MSc. MBA</last_name>
    <phone>+972 3 541 3131</phone>
    <email>aida@redhillbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gina Eagle, MD</last_name>
    <phone>972 (0)3 541 3131</phone>
    <email>ginaeagle@getpharmaconsulting.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-1225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility 1</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility 2</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33870</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Valdosta</city>
        <state>Georgia</state>
        <zip>31605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MAC</keyword>
  <keyword>Bronchiectasis</keyword>
  <keyword>NTM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

